quadrivalent groups a, c, y, and w-135 meningococcal vaccine
Trade name: Menomune-A/C/Y/W-135
Vaccineapproved
Approved
Nov 23, 1981
Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin. — Wikipedia
Clinical trial activity
42 trials · 31 clinical orgs · 2 marketing orgs
Phase 1
6
Phase 2
33
Phase 3
16
Phase 4
4
Earliest trial started Apr 1, 2001 (NCT00239694)
Timeline
1980s
- Nov 23, 1981
Earliest FDA Approval
1990s
- Dec 9, 1999
Sanofi-Aventis — First NDA Organization
- Dec 9, 1999
Sanofi-Aventis — NDA Secondary Org
- Dec 9, 1999
Sanofi-Aventis — NDA Organization
2000s
2010s
- Feb 19, 2010
GlaxoSmithKline — NDA Secondary Org
Indications
Approved for
Studied for
- Aging · Phase 4
- Haemophilus influenzae type b · Phase 2
- Healthy Volunteers · Phase 3
- HIV Infections · Phase 1/Phase 2
- Immunization · Phase 4
- Meningitis · Phase 4
- Meningitis, Bacterial · Phase 3
- Meningitis, Meningococcal · Phase 4
- Meningococcal Infections · Phase 4
- Neisseria meningitidis · Phase 2
- Pneumococcal Infections · Phase 4
- Whooping Cough · Phase 4
Mechanism of action
- Neisseria meningitidisImmunity, active
Neisseria meningitidis immunity, active
Approval history
- approvedNov 23, 1981
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMeningococcal vaccine ↗
Also known as
- acyw135 meningococcal polysaccharide vaccine
- group a, c, y and w135 meningococcal polysaccharide vaccine
- group a, c, y & w-135 meningococcal polysaccharide diphtheria toxoid conjugate vaccine
- meningococcal abcwy vaccine
- meningococcal acwy conjugate vaccine
- meningococcal acwy vaccine
- menomune
- menomune a/c/y/w-135
- quadrivalent groups a, c, y, and w-135 meningococcal vaccine
- quadrivalent meningococcal conjugate vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05794230 | Phase 3 | Mar 27, 2023 | Sanofi-Aventis |
| NCT03890367 | Phase 3 | Jul 19, 2019 | Sanofi-Aventis |
| NCT03869866 | Phase 3 | Feb 20, 2019 | Sanofi-Aventis |
| NCT03547271 | Phase 3 | Nov 30, 2018 | Sanofi-Aventis |
| NCT03630705 | Phase 3 | Oct 31, 2018 | Sanofi-Aventis |
| NCT03673462 | Phase 3 | Sep 17, 2018 | Sanofi-Aventis |
| NCT02946385 | Phase 2 | Nov 15, 2016 | GlaxoSmithKline |
| NCT02869672 | Phase 3 | Jul 1, 2016 | Capital Medical University |
| NCT02867319 | Phase 1 | Mar 1, 2016 | Capital Medical University |
| NCT03205358 | Phase 2 | Mar 31, 2015 | Sanofi-Aventis |
| NCT02285777 | Phase 2 | Dec 1, 2014 | GlaxoSmithKline |
| NCT02212457 | Phase 2 | Aug 1, 2014 | Novartis |
| NCT01889836 | Phase 1 | May 1, 2014 | Oswaldo Cruz Foundation |
| NCT02003313 | Phase 3 | Nov 1, 2013 | Beijing Minhai Biotechnology Co., Ltd, Government of China |
| NCT02526394 | Phase 4 | Sep 1, 2013 | Public Health England |
| NCT01897402 | Phase 2 | Jul 1, 2013 | Chesapeake Research Group, LLC, IRC Clinics, Towson, JN-International Medical Corporation |
| NCT01967238 | N/A | Mar 1, 2013 | Rockefeller University |
| NCT01547715 | Phase 3 | Mar 1, 2012 | Bharati Hospital and Research Center, Dr. D. Y. Patil Dental College & Hospital, Niloufer Hospital, Hyderabad, Novartis, Seth Gordhandas Sunderdas Medical College |
| NCT01410474 | Phase 3 | Aug 1, 2011 | Far Eastern Memorial Hospital, Mackay Medical College, National Taiwan University, Novartis |
| NCT01210885 | Phase 2 | Dec 1, 2010 | Novartis |
Showing 20 of 42 trials
Page 1 / 3
Organizations
Research & Development (31)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 10 | 9 | 2 | 2007 |
| Sanofi-Aventis | For profit | 7 | 7 | 2 | 2015 |
| GlaxoSmithKline | For profit | 6 | 6 | 1 | 2003 |
| Sanofi | For profit | 5 | 5 | 2 | 2003 |
| Government of China | Government | 4 | 0 | 3 | 2006 |
| Hualan Biological Engineering, Inc. | For profit | 3 | 3 | 3 | 2006 |
| Public Health England | Government | 3 | 3 | 2 | 2005 |
| Capital Medical University | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Health Protection Agency, United Kingdom | Government | 2 | 0 | 2 | 2005 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 2 | 2001 |
| Beijing Minhai Biotechnology Co., Ltd | For profit | 1 | 1 | 1 | 2013 |
| Bharati Hospital and Research Center | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Chesapeake Research Group, LLC | For profit | 1 | 0 | 1 | 2013 |
| Dr. D. Y. Patil Dental College & Hospital | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Epicentre | For profit | 1 | 1 | 1 | 2004 |
| Far Eastern Memorial Hospital | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Government of Norway | Government | 1 | 0 | 1 | 2004 |
| IRC Clinics, Towson | Academic/Hospital | 1 | 0 | 1 | 2013 |
| JN-International Medical Corporation | For profit | 1 | 1 | 1 | 2013 |
| Mackay Medical College | Academic/Hospital | 1 | 0 | 1 | 2011 |
31 organizations
Page 1 / 2
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| GlaxoSmithKline | For profit | NDA2 | Feb 19, 2010 |
| Sanofi-Aventis | For profit | NDA2 | Dec 9, 1999 |
| Sanofi-Aventis | For profit | NDA | Dec 9, 1999 |